Key result
This review discusses the molecular mechanisms of MYBPC3 mutations in hypertrophic cardiomyopathy and highlights novel therapeutic targets.
This review summarizes the molecular mechanisms of MYBPC3 mutations in hypertrophic cardiomyopathy and identifies potential novel therapeutic targets.
Clarifies MYBPC3 mutation mechanisms in HCM; leaves targeted therapies open pending functional validation.
Hypertrophic cardiomyopathy (HCM) is a common autosomal dominant genetic cardiovascular disorder marked by genetic and phenotypic heterogeneity. Mutations in the gene encodes the cardiac myosin-binding protein C, cMYBPC3 is amongst the various sarcomeric genes that are associated with HCM. These mutations produce mutated mRNAs and truncated cMyBP-C proteins. In this review, we will discuss the implications and molecular mechanisms involved in MYBPC3 different mutations. Further, we will highlight the novel targets that can be developed into potential therapeutics for the treatment of HMC. J. Cell. Physiol. 232: 1650-1659, 2017.
No takes yet. Share an insight, caveat, or question.
Mohamed et al. (2016) conducted a review in Hypertrophic cardiomyopathy. MYBPC3 mutations and novel therapeutic targets was evaluated. This review discusses the molecular mechanisms of MYBPC3 mutations in hypertrophic cardiomyopathy and highlights novel therapeutic targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: